Wells Fargo & Company Pacira Bio Sciences, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 40,798 shares of PCRX stock, worth $817,183. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,798
Previous 37,076
10.04%
Holding current value
$817,183
Previous $1.25 Million
4.64%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PCRX
# of Institutions
291Shares Held
48.5MCall Options Held
156KPut Options Held
623K-
Black Rock Inc. New York, NY7.91MShares$158 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$102 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.91MShares$38.3 Million0.55% of portfolio
-
State Street Corp Boston, MA1.9MShares$38.1 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$37.7 Million0.09% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $918M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...